MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.

Alexander G. Raufi,Winston Wong,Shing Mirn Lee,Gulam Abbas Manji

MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.

2021

Alexander G. Raufi
Winston Wong
Shing Mirn Lee
Gulam Abbas Manji

TPS450Background: Pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma (CRC) are aggressive diseases which account for the third and second leading causes of cancer-related death, respe...

Keywords:

Hydroxychloroquine
Atezolizumab
Blockade
KRAS
Cobimetinib
MEK inhibitor
Combination therapy
Medicine
Immune checkpoint
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations